BioCryst Pharma (BCRX) Misses Q4 EPS by 6c; offers outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. SAP
8. LRCX
9. MRK
10. LVS

Go back to BioCryst Pharma (BCRX) Misses Q4 EPS by 6c; offers outlook

Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)

February 24, 2025 1:18 PM EST

Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $23.00 price target on BioCryst Pharma (NASDAQ: BCRX)

The analyst comments "Remain OW rated on BCRX shares after a solid Q424 Orladeyo print, reporting $124.2M versus the $123.5M preliminary revenue pre-released last month.... More

JPMorgan Reiterates Overweight Rating on BioCryst Pharma (BCRX)

February 24, 2025 8:58 AM EST

JPMorgan analyst Jessica Fye reiterated an Overweight rating and $10.00 price target on BioCryst Pharma (NASDAQ: BCRX)

The analyst comments "We think the ~3% upward guidance revision to FY25 Orladeyo revs by ~$18mm at the midpoint to $535-$550mm (vs prior guidance of $515-$535mm established earlier this year at our healthcare conference) will be well received as it supports 24% growth YoY for Orladeyo at the midpoint after 34% Orladeyo growth in 24. Well listen... More